Divergent Proteome Reactivity Influences Arm-Selective Activation of the Unfolded Protein Response by Pharmacological Endoplasmic Reticulum Proteostasis Regulators by Gabriel M. Kline (16716069)

“…Another compound identified in this screen, AA132, also contains a 2-amino-<i>p</i>-cresol moiety; however, this compound showed less transcriptional selectivity, instead globally activating all three arms of the UPR. …”

Divergent Proteome Reactivity Influences Arm-Selective Activation of the Unfolded Protein Response by Pharmacological Endoplasmic Reticulum Proteostasis Regulators by Gabriel M. Kline (16716069)

“…Another compound identified in this screen, AA132, also contains a 2-amino-<i>p</i>-cresol moiety; however, this compound showed less transcriptional selectivity, instead globally activating all three arms of the UPR. …”

Divergent Proteome Reactivity Influences Arm-Selective Activation of the Unfolded Protein Response by Pharmacological Endoplasmic Reticulum Proteostasis Regulators by Gabriel M. Kline (16716069)

“…Another compound identified in this screen, AA132, also contains a 2-amino-<i>p</i>-cresol moiety; however, this compound showed less transcriptional selectivity, instead globally activating all three arms of the UPR. …”

Divergent Proteome Reactivity Influences Arm-Selective Activation of the Unfolded Protein Response by Pharmacological Endoplasmic Reticulum Proteostasis Regulators by Gabriel M. Kline (16716069)

“…Another compound identified in this screen, AA132, also contains a 2-amino-<i>p</i>-cresol moiety; however, this compound showed less transcriptional selectivity, instead globally activating all three arms of the UPR. …”

Divergent Proteome Reactivity Influences Arm-Selective Activation of the Unfolded Protein Response by Pharmacological Endoplasmic Reticulum Proteostasis Regulators by Gabriel M. Kline (16716069)

“…Another compound identified in this screen, AA132, also contains a 2-amino-<i>p</i>-cresol moiety; however, this compound showed less transcriptional selectivity, instead globally activating all three arms of the UPR. …”

Fenretinide: A Novel Treatment for Endometrial Cancer by Navdha Mittal (650261)

“…Immunohistochemistry of mice tumors showed a decrease in Ki67 expression and an increase in cleaved caspase-3 staining after fenretinide treatment when compared to vehicle treated mice. …”

Influence of Terminal Carboxyl Groups on the Structure and Reactivity of Functionalized <i>m</i>‑Carboranethiolate Self-Assembled Monolayers by Dominic P. Goronzy (2624401)

“…Here, two geometrically similar isomeric <i>m</i>-carborane analogues of <i>m</i>-mercaptobenzoic acid, 1-COOH-7-SH-1,7-C₂B₁₀H₁₀ and <i>racem</i>-1-COOH-9-SH-1,7-C₂B₁₀H₁₀, are characterized and their SAMs on Au{111} are examined. …”

Influence of Terminal Carboxyl Groups on the Structure and Reactivity of Functionalized <i>m</i>‑Carboranethiolate Self-Assembled Monolayers by Dominic P. Goronzy (2624401)

“…Here, two geometrically similar isomeric <i>m</i>-carborane analogues of <i>m</i>-mercaptobenzoic acid, 1-COOH-7-SH-1,7-C₂B₁₀H₁₀ and <i>racem</i>-1-COOH-9-SH-1,7-C₂B₁₀H₁₀, are characterized and their SAMs on Au{111} are examined. …”

Differential gene expression triggered by serum depletion in culture. by Pedro J. Alcolea (553038)

Mechanisms of hidden hearing loss. by Maral Budak (6680351)

“…<p>(A) Experimental results suggest that different mechanisms of HHL, myelinopathy (left) and noise exposure resulting in synaptopathy (middle), affects ABR peak 1 (P1) in distinct ways: Myelinopathy increases ABR P1 latency and decreases ABR P1 amplitude, while synaptopathy induced by noise exposure decreases ABR P1 amplitude only, without any change in latency. …”

The localization patterns of SPB, <i>CEN V</i> and <i>TEL V</i> during different stages of the mitotic cell cycle. by Deepanshu Kumar (11146875)

Plot of the between cluster inertia for group 2. by Pasquale Musso (12400652)

Fig 6 - by Matthew C. Kochem (18476069)

Fig 2 - by Matthew C. Kochem (18476069)

Fig 5 - by Matthew C. Kochem (18476069)

Fig 1 - by Matthew C. Kochem (18476069)

Participant traits. by Matthew C. Kochem (18476069)

Fig 4 - by Matthew C. Kochem (18476069)

Fig 3 - by Matthew C. Kochem (18476069)

Evaluation of the PCSK9 vaccine (V2 vaccine) in male <i>ApoE-deficient mice</i> (N = 5–7). by Ryo Kawakami (4849549)